|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking
|
| Published Date:
May 2009
Published By:
Decision Resources
Page Count:
24
Order Code:
R55-645
|
|
|
|
Introduction
Today’s leading autoimmune/inflammatory disease drugs are blockbusters, but what are the remaining unmet needs and next opportunities? Dealmaking patterns indicate that Big Pharma continues to look to small technology companies to tap opportunities to treat underserved diseases and offer improved administration options. While the value of the novel agents in development remains unproved, earlystage platforms and pipelines house the next innovations in these disease states.
Get the Answers You Need to Shape Your Strategy
- Although efficacious, current therapies for inflammatory and autoimmune diseases do not successfully
treat all patients. What novel mechanisms of action are in development? What technologies offer treatment potential?
- Much of the innovation in drug discovery and design occurs in small companies. What companies are developing novel approaches to treat inflammatory diseases? What collaborations have they forged with Big Pharma?
- Although the inflammatory cascade is central to most of the autoimmune diseases, the specific etiology
of many diseases remains unknown. What are companies doing to further the understanding of these diseases?
Scope
- Current market: 2008 sales, market-leading products, leading companies.
- Novel targets for drug development: MAP kinases, Janus kinases, toll-like receptors,novel interleukins, NF-ęB, PDE4.
- Novel technologies for drug development: RNA therapeutics, stem-cell therapy.
- Development and dealmaking data: 8 tables that identify developmental compounds and industry and academic alliances.
- Company profiles: Archemix, Array BioPharma, Cellzome, Dynavax, Regulus Therapeutics.
|
Similar Products
Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.
Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.
Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC
Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
|
|
|
|
0 items
